Ai-Wen Wu1, Jin Gu, Jia-Fu Ji, Zhen-Fu Li, Guang-Wei Xu. 1. Department of Surgery, Peking University, School of Oncology, Beijing Cancer Hospital, Beijing Institute of Cancer Research, China.
Abstract
AIM: Recent clinical epidemiological studies have demonstrated the preventive effect of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer. The underlying mechanism might be the inhibition of rate-limiting enzyme cyclooxygenase-2 (COX-2) in metabolism of arachidonic acid. The role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis still remain unclear. This study was to investigate the role of COX-2 expression in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. METHODS: A total of 139 colorectal cancers and 19 adenomas surgically treated in School of Oncology, Peking University, from January 1993 to September 2001 were retrospectively studied. COX-2 expression was detected with tissue microarray (TMA) and immunohistochemistry (IHC) procedure. The association between COX-2 expression and clinicopathological features and its influence on patients' prognosis were studied. RESULTS: COX-2 expression was strong in colorectal cancer, moderate in adenoma and weak in normal mucosa, which demonstrated statistically significant difference (chi(2)=46.997, P<0.001). COX-2 expression had no association with clinicopathological features such as gross type, differentiation, invasion depth, vessel emboli and TNM staging. Cox proportional hazards modeling analysis and Log rank test revealed no prognostic role of COX-2 expression in colorectal cancer patients. CONCLUSION: COX-2 may play an important role in the early stage of carcinogenesis, and its expression in colorectal cancer is not associated with clinicopathological features and patients' prognosis.
AIM: Recent clinical epidemiological studies have demonstrated the preventive effect of non-steroidal anti-inflammatory drugs (NSAIDs) against colorectal cancer. The underlying mechanism might be the inhibition of rate-limiting enzyme cyclooxygenase-2 (COX-2) in metabolism of arachidonic acid. The role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis still remain unclear. This study was to investigate the role of COX-2 expression in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. METHODS: A total of 139 colorectal cancers and 19 adenomas surgically treated in School of Oncology, Peking University, from January 1993 to September 2001 were retrospectively studied. COX-2 expression was detected with tissue microarray (TMA) and immunohistochemistry (IHC) procedure. The association between COX-2 expression and clinicopathological features and its influence on patients' prognosis were studied. RESULTS:COX-2 expression was strong in colorectal cancer, moderate in adenoma and weak in normal mucosa, which demonstrated statistically significant difference (chi(2)=46.997, P<0.001). COX-2 expression had no association with clinicopathological features such as gross type, differentiation, invasion depth, vessel emboli and TNM staging. Cox proportional hazards modeling analysis and Log rank test revealed no prognostic role of COX-2 expression in colorectal cancerpatients. CONCLUSION:COX-2 may play an important role in the early stage of carcinogenesis, and its expression in colorectal cancer is not associated with clinicopathological features and patients' prognosis.
Authors: Y Takebayashi; K Nakayama; A Kanzaki; H Miyashita; O Ogura; S Mori; M Mutoh; K Miyazaki; M Fukumoto; Y Pommier Journal: Cancer Lett Date: 2001-12-28 Impact factor: 8.679
Authors: R Masunaga; H Kohno; D K Dhar; S Ohno; M Shibakita; S Kinugasa; H Yoshimura; M Tachibana; H Kubota; N Nagasue Journal: Clin Cancer Res Date: 2000-10 Impact factor: 12.531
Authors: S Tomozawa; H Nagawa; N Tsuno; K Hatano; T Osada; J Kitayama; E Sunami; M E Nita; S Ishihara; H Yano; T Tsuruo; Y Shibata; T Muto Journal: Br J Cancer Date: 1999-12 Impact factor: 7.640
Authors: Christian Lang; Emilie Hrdliczka; Thomas Schweiger; Olaf Glueck; Gerrit Lewik; Stefan Schwarz; Alberto Benazzo; György Lang; Walter Klepetko; Konrad Hoetzenecker Journal: J Thorac Dis Date: 2017-03 Impact factor: 2.895
Authors: Ashley E Stewart; Martin H Heslin; Jorge Arch; Nirag Jhala; Brian Ragland; Fernando Gomez; Kirby I Bland; J Pablo Arnoletti Journal: J Gastrointest Surg Date: 2006-02 Impact factor: 3.452
Authors: Annelies Debucquoy; Laurence Goethals; Louis Libbrecht; Christiaan Perneel; Karel Geboes; Nadine Ectors; William H McBride; Karin Haustermans Journal: Int J Colorectal Dis Date: 2008-12-03 Impact factor: 2.571
Authors: Kari Almendingen; Laila N Larsen; Olav Fausa; Jorunn Bratlie; Arne T Høstmark; Lars Aabakken Journal: Fam Cancer Date: 2010-12 Impact factor: 2.375
Authors: Shuji Ogino; Gregory J Kirkner; Katsuhiko Nosho; Natsumi Irahara; Shoko Kure; Kaori Shima; Aditi Hazra; Andrew T Chan; Reiko Dehari; Edward L Giovannucci; Charles S Fuchs Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531
Authors: Ni Shi; Kenneth M Riedl; Steven J Schwartz; Xiaoli Zhang; Steven K Clinton; Tong Chen Journal: J Funct Foods Date: 2016-09-16 Impact factor: 4.451